Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menstrual blood-derived stem cell ovarian injection for premature ovarian failure
IRCT20180619040147N1Phase 2Completed
- Sponsor
- ACECR
- Start
- Jul 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous menstrual blood-derived stem cells in ovarian hypofunction (POI) (2 arms), sponsored by ACECR. Primary endpoints: Antral follicle number, Antral follicle size and 5 more. Started Jul 2018; status: completed.
02
Drugs
autologous menstrual blood-derived stem cells
03
Conditions
ovarian hypofunction (POI)
Beyond the preview
Go deeper on IRCT20180619040147N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180619040147N1.